Beam Therapeutics BEAM 深 沪
已收盘 11-13 16:00:00 美东时间
22.83
-1.200
-4.99%
华盛通- 最 高24.055
- 今 开24.03
- 成交量 204.56万股
- 最 低 22.81
- 昨 收 24.03
- 总市值 23.63亿
- 52周最高 38.26
- 市盈率 静 --
- 换手率 1.98%
- 52周最低 21.63
- 委 比 -90.48%
- 总股本 1.03亿
- 历史最高 138.522
- 量 比 1.08
- 振 幅 5.18%
- 历史最低 13.00
- 每 手 1
- 风险率 3.26%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | Stifel等多家大行上调CoreWeave目标价；杰富瑞首予康宁"买入"评级
今日重点评级关注：韦德布什：维持Cullinan Therapeutics"跑赢大市"评级，目标价从42美元升至44美元；HC Wainwright & Co.：维持WhiteFiber"买入"评级，目标价从34美元升至36美元
11-12 19:19
Short Interest Powder Kegs: 10 Stocks Bears Cannot Quit Buying
Bears are crowding into a small group of stocks, and one name has nearly its entire float sold short. Venture Global Inc. (NYSE:VG) leads the market’s most heavily shorted stocks at 90.11% of float, according to Benzinga Pro data. Nine other companies carry short interest above 34%, a mix of big 202...
11-12 00:44
Wedbush Maintains Outperform on Beam Therapeutics, Raises Price Target to $33
Wedbush analyst David Nierengarten maintains Beam Therapeutics (NASDAQ:BEAM) with a Outperform and raises the price target from $30 to $33.
11-11 22:12
美股大行评级 | 可口可乐、麦当劳、3M等获多家大行看好；机构上调高通目标价至165美元
今日重点评级关注：Citizens：维持Precigen"跑赢大市"评级，目标价从11美元升至12美元；Leerink Partners：维持Arcus Biosciences"跑赢大市"评级，目标价从46美元升至49美元
11-06 16:15
美股大行评级 | 大摩上调AMD目标价至725美元；安进、多邻国绩后获华尔街大行看多
今日重点评级关注：康托·菲茨杰拉德：维持Supernus"超配"评级，目标价从67美元升至87美元；丰业银行：维持Atlas Energy Solutions"跑赢大市"评级，目标价从17美元升至18美元
11-05 14:06
Beam Therapeutics To Present Updated Data From Its BEACON Phase 1/2 Study Of Ristoglogene Autogetemcel In Sickle Cell Disease At 68th American Society of Hematology Annual Meeting
Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will present updated data from the BEACON Phase 1/2 clinical trial of ristoglogene autogetemcel (risto-cel) in sickle cell disease (SCD) in an ...
11-04 22:04
Beam Therapeutics to Present Updated Clinical Data from BEACON Phase 1/2 Trial of Risto-cel in Sickle Cell Disease in an Oral Presentation at American Society of Hematology (ASH) Annual Meeting
Beam Therapeutics announced positive interim results from the BEACON Phase 1/2 trial of ristoglogene autogetemcel (risto-cel) for sickle cell disease (SCD), showing early and sustained improvements in physical function, pain, fatigue, and overall well-being. The findings will be presented at the 68th ASH Annual Meeting in December 2026 and selected for ASH’s official press program. Risto-cel, an investigational gene-edited cell therapy, aims to i...
11-04 14:00
财报速睇 | Beam Therapeutics 2026财年Q3营收0.00亿美元，同比下降96.8%；归母净利润亏损1.34亿美元，同比亏损扩大19.4%
华盛资讯11月3日讯，Beam Therapeutics公布2026财年Q3业绩，公司Q3营收0.00亿美元，同比下降96.8%，归母净利润亏损1.34亿美元，同比亏损扩大19.4%。
11-03 21:47
Beam Therapeutics Q3 EPS $(1.28) Misses $(1.15) Estimate, Sales $307.000K Miss $8.752M Estimate
Beam Therapeutics (NASDAQ:BEAM) reported quarterly losses of $(1.28) per share which missed the analyst consensus estimate of $(1.15) by 11.3 percent. This is a 16.36 percent decrease over losses of $(1.10) per share from the same period last year. The company reported quarterly sales of $307.000 th...
11-03 20:08
今日“木头姐”调仓：连续两日增持Cerebras，减持Tempus AI
10月29日，“木头姐”凯茜·伍德旗下ARK投资管理公司公布最新交易记录，当天最大一笔买入为AI芯片制造商Cerebras Systems，通过ARKK和...
10-30 14:29
